Table 3. Other Studies Investigating Bradyarrhythmia After Remdesivir Administration in SARS-CoV-2 Patients.
| Study | Country | Design | Sample size | Male cases (%) | Findings |
|---|---|---|---|---|---|
| Brunetti et al [24] | Italy | Case series | 52 | 56 | Mean heart rate reduction 24 ± 16 bpm after RDV administration |
| Bistrovic and Lucijanic [26] | Croatia | Prospective cohort | 14 | 64 | Statistically significant rightward T-axis deviation association with RDV |
| Eleftheriou et al [23] | Greece | Case series | 4 | 25 | Third-fourths (75%) pediatric patients treated with RDV developed asymptomatic bradycardia |
| Elikowski et al [22] | Poland | Case series | 19 | 63.2 | 12/19 (63%) patients that developed transient SB were on RDV |
| Rodriguez-Guerra et al [25] | USA | Retrospective cohort | 37 | 51.4 | 43% of patients on RDV developed bradycardia |
| Bistrovic et al [27] | Croatia | Retrospective cohort | 473 | 66 | Bradycardia on day 5 of RDV was significantly associated with lower odds of death (OR 0.33 (95% CI: 0.16 - 0.79); P = 0.014) |
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; RDV: remdesivir; SB: sinus bradycardia; OR: odds ratio; CI: confidence interval.